Skip to main content
logo
Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
13.30
+0.07 (0.57%)
Aug 6, 2026, 2:11 PM EDT - Market open

Enanta Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Oct - Sep.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Revenue
69.2165.3267.6479.286.1697.07
Revenue Growth
7.37%-3.42%-14.61%-8.07%-11.24%-20.74%
Gross Profit
69.2165.3267.6479.286.1697.07
Operating Income
-60.38-85.35-121.69-137.21-123.84-109.57
Net Income
-61.98-81.89-116.05-133.82-121.76-79
Earnings Per Share
-2.59-3.84-5.48-6.38-5.91-3.92
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Cash & Investments
163.77188.86248.19369.91249.23244
Total Debt
56.5457.955.4726.5125.265.33
Net Cash (Debt)
107.24130.96192.72343.4223.97238.67
Net Cash Growth
-20.35%-32.05%-43.88%53.32%-6.16%-36.95%
Net Cash Per Share
4.276.149.1116.3810.8711.83

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Operating Cash Flow
-7.84-19.27-78.76-103.15-84.78-70
Capital Expenditures
-1.77-12.9-17.95-9.06-2.13-0.75
Free Cash Flow
-9.61-32.17-96.71-112.21-86.91-70.75
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-87.24%-130.66%-179.92%-173.23%-143.74%-112.88%
Pretax Margin
-89.42%-127.90%-174.15%-165.39%-141.82%-110.82%
Profit Margin
-89.56%-125.36%-171.58%-168.95%-141.31%-81.38%
FCF Margin
-13.88%-49.24%-142.99%-141.67%-100.87%-72.88%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Forward PE
-6.266.266.266.26105.09
PS Ratio
5.553.923.252.9712.5211.84